Orexo's Zubsolv could take market share from Suboxone, report suggests

30 October 2013

Edison Equity Research analysts say that expected new clinical data from Swedish drug developer Orexo (STO: ORX) could benefit the company’s share price.

Their report said that Orexo is focused on securing competitive reimbursement to drive Zubsolv (buprenorphine/naloxone) sublingual tablet CIII sales growth in the USA.

New clinical data next year could expand Zubsolv’s current label for use as maintenance treatment for people suffering from opioid dependence and take market share from UK-headquartered Reckitt Benckiser (LSE: RBL) Suboxone (buprenorphine), which had 85% market share with more than $1.5 billion of sales last year. Zubsolv may also benefit from the limited impact of Suboxone generics and speculation about Reckitt’s intention to divest its pharma division, the analysts added.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK